Navigation Links
Currently approved drugs found effective in laboratory mice against bioterror threats
Date:4/11/2013

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses. The pathogens included emerging diseases and potential bioterror threats ranging from anthrax to the Marburg and Ebola viruses.

In testing a library of 1,012 Food and Drug Administration-approved drugs, commonly used for treatment of every-day ailments like diabetes and high blood pressure, the scientists found that ten were active against two or more bacteria and that 24 were active against two or more viruses.

Two drugs were found to be the most potent compounds in protecting mice against anthrax while one drug, chloroquine, once used to treat malaria, protected mice against Ebola virus, said Robert Davey, Ph.D., a Texas Biomed virologist.

The new study, which included authors Jean Patterson, Ph.D., and Ricardo Carrion, Ph.D., both of Texas Biomed, appears in the April 2013 issue of the journal PLOS ONE. Their findings came from a collaborative effort among Texas Biomed, independent research institute SRI International and the U.S. Army Medical Research Institute of Infectious Diseases. It was supported by funds from the Defense Threat Reduction Agency, the Defense Department's agency for countering weapons of mass destruction.

"Repurposing of existing drugs that may have unanticipated activities as potential countermeasures is one way to meet this important goal, since currently approved drugs already have well-established safety and pharmacokinetic profiles in patients, and manufacturing and distribution networks," the authors wrote. "Therefore, approved drugs could rapidly be made available for a new indication in an emergency."

The scientists found a variety of hits against two or more of these bio-threat pathogens, which were validated in secondary tests. As expected, antibiotic compounds were highly active against bacterial agents, but the researchers did not identify any non-antibiotic compounds with broad spectrum antibacterial activity.

Lomefloxacin and erythromycin were found to be the most potent compounds in protecting mice against anthrax. Lomeflaxacin is used to treat bronchitis and urinary tract infections. Erythromycin is used against respiratory tract infections.

The most noteworthy antiviral compound identified was chloroquine which disrupted virus entry and replication in cells of two or more viruses in vitro and protected mice against Ebolavirus.

Due to the demanding complexity of working with these agents under laboratory conditions as well as the fact that human drug clinical trials cannot be ethically conducted for any of these agents, conventional drug discovery and development approaches are particularly challenging. For these agents, the FDA must evaluate the efficacy of drugs on the basis of their activities in appropriate animal models, under agency guidance. Thus, drug-repurposing offers many advantages, particularly given the fact that human safety studies have already been conducted.

Members of the Texas Biomed team are presently pursuing whether the other drugs could be equally useful for treatment of these viruses.

"It would be important to determine if a combination of drugs could be more potent than each individual drug," Davey said. "Such synergy, when seen, usually means you can lower the dose of each drug and still have a big impact on the disease while minimizing bad side effects. Such work could prove useful as an easy frontline defense against these viruses."


'/>"/>

Contact: Joseph Carey
jcarey@txbiomed.org
210-258-9437
Texas Biomedical Research Institute
Source:Eurekalert

Related biology technology :

1. iBio, Inc. Receives Notice from NYSE MKT Staff that Company Currently is Below Certain Continued Listing Standards
2. Tri-Valley Dentist Dr. Endre Selmeczy Currently Features Oral Sedation Dentistry
3. Upsher-Smith Currently Recruiting People With Epilepsy To Evaluate Investigational Rescue Treatment For Seizure Clusters
4. Indoor Air Quality Professionals Provide New Expert Witness Services To Help Mold Victims Get Mold Claims Approved and Win in Court, AGCEnvironmental Explains How
5. Cardiometabolic Health Congress Expert Faculty Evaluate the Clinical Implications of Newly FDA-Approved Treatment for Homozygous Familial Hypercholesterolemia
6. Recently FDA-Approved Full Neck Treatment for Sagging Skin Now Available at Maryland Laser Skin and Vein Institute
7. Pinnaclife Animal Health Features Seal N Heal Wound Shield in New Veterinary Dermatologist Tested and Approved Product Line!
8. K-V Pharmaceutical Use of Cash Collateral Approved by U. S. Bankruptcy Court
9. K-V Pharmaceutical "First Day" Motions Approved by U.S. Bankruptcy Court
10. SpermCheck® Fertility, the Only FDA Approved At-Home Screening Test for Men to Determine Normal or Low Sperm Count, Now Available to Couples Planning or Struggling to Conceive
11. Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 18, 2017 Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced that Dr. ... CEO of Applied BioMath, will present at the ... (BAGIM) Meeting on Thursday January 19, 2017 at ... , MA.   Dr. Burke,s talk "Quantitative Modeling and ...
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers are ... Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including Pfizer, ... such as trial performance metrics, patient enrollment diversity, protocol optimization, and global site ...
(Date:1/18/2017)... , Jan. 18, 2017 Shareholder rights ... investigation into whether the board members of CoLucid Pharmaceuticals, ... duties in connection with the proposed sale of the ... biopharmaceutical company that develops small molecules for the acute ... CoLucid announced it had signed a definitive merger agreement ...
Breaking Biology Technology:
(Date:1/11/2017)... , Jan. 11, 2017 Intoxalock, a ... with the release of its patent-pending calibration device. With ... reliably perform calibrations, securely upload data logs and process ... the customer. "Fighting drunk driving through the ... the public at large, but also for the customer ...
(Date:1/6/2017)... , Jan. 5, 2017  Delta ID Inc., ... iris scanning technology for automotive at CES® 2017. Delta ... GNTX ) to demonstrate the use of iris scanning ... and authenticate the driver in a car, and as ... the driving experience. Delta ID and Gentex ...
(Date:12/22/2016)... MOUNTAIN VIEW, Calif. , Dec. 20, 2016  As ... all levels, 23andMe, the leading personal genetics company, recently released ... Only Me . The book focuses on the topics ... the Next Generation Science Standards (NGSS) taught in elementary school ... the second in a series by illustrator Ariana Killoran ...
Breaking Biology News(10 mins):